Purpose: The combination of two tumour markers, CA125 and HE4, in the risk of ovarian malignancy assay (ROMA) has been shown to be successful in classifying patients into those who have a high or low risk of epithelial ovarian cancer. In the present study, the diagnostic accuracy of ROMA was assessed and compared to the diagnostic accuracy of the two most widely used ultrasound methods, namely the risk of malignancy index (RMI) and subjective assessment by ultrasound. Methods: From August, 2005 to March, 2009, 432 women with a pelvic mass who were scheduled to have surgery were enrolled in a single-centre prospective cohort study. A preoperative ultrasound was performed and preoperative CA125 and HE4 serum levels were measured. Once the fin...
Objective To determine whether serum human-epididymis protein-4 (HE4) levels or Risk of Ovarian Mali...
OBJECTIVES: To determine whether CA 125 measurement is superior to ultrasound imaging performed by a...
Purpose: Ovarian cancer is the fourth cause of death from cancer in women worldwide and the majority...
Purpose: The combination of two tumour markers, CA125 and HE4, in the risk of ovarian malignancy ass...
Introduction: Many national guidelines concerning the management of ovarian cancer currently advocat...
Objective. The identification of novel biomarkers led to the development of the ROMA algorithm incor...
Objectives: To evaluate the validity and compare the performance of cancer antigen-125 (CA-125), hum...
Many national guidelines concerning the management of ovarian cancer currently advocate the risk of ...
Background: Different ultrasound based models, rules and descriptors are used to characterise ovaria...
The accurate prediction of malignancy for a pelvic mass detected on ultrasound allows for appropriat...
OBJECTIVE: Differentiation between benign and malignant ovarian neoplasms is essential for creating ...
(1) OBJECTIVE: To assess the performance of CA125, HE4, ROMA index and CPH-I index to preoperatively...
risk of malignancy index (RMI) — in differentiating between benign and borderline or malignant ovari...
Objective To evaluate the ability of two malignancy risk indices (RMI 1 and Rh4I 2) incorporating me...
Objectives To evaluate the capacity to predict malignancy in women with adnexal tumors using CA 125 ...
Objective To determine whether serum human-epididymis protein-4 (HE4) levels or Risk of Ovarian Mali...
OBJECTIVES: To determine whether CA 125 measurement is superior to ultrasound imaging performed by a...
Purpose: Ovarian cancer is the fourth cause of death from cancer in women worldwide and the majority...
Purpose: The combination of two tumour markers, CA125 and HE4, in the risk of ovarian malignancy ass...
Introduction: Many national guidelines concerning the management of ovarian cancer currently advocat...
Objective. The identification of novel biomarkers led to the development of the ROMA algorithm incor...
Objectives: To evaluate the validity and compare the performance of cancer antigen-125 (CA-125), hum...
Many national guidelines concerning the management of ovarian cancer currently advocate the risk of ...
Background: Different ultrasound based models, rules and descriptors are used to characterise ovaria...
The accurate prediction of malignancy for a pelvic mass detected on ultrasound allows for appropriat...
OBJECTIVE: Differentiation between benign and malignant ovarian neoplasms is essential for creating ...
(1) OBJECTIVE: To assess the performance of CA125, HE4, ROMA index and CPH-I index to preoperatively...
risk of malignancy index (RMI) — in differentiating between benign and borderline or malignant ovari...
Objective To evaluate the ability of two malignancy risk indices (RMI 1 and Rh4I 2) incorporating me...
Objectives To evaluate the capacity to predict malignancy in women with adnexal tumors using CA 125 ...
Objective To determine whether serum human-epididymis protein-4 (HE4) levels or Risk of Ovarian Mali...
OBJECTIVES: To determine whether CA 125 measurement is superior to ultrasound imaging performed by a...
Purpose: Ovarian cancer is the fourth cause of death from cancer in women worldwide and the majority...